Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;197(4):e49-e52.
doi: 10.1111/bjh.18044. Epub 2022 Feb 6.

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Amy Zhou  1 , Tim Kong  1 , Jared S Fowles  1 , Chun-Ling Jung  2 , Maggie J Allen  1 , Daniel A C Fisher  1 , Mary Fulbright  1 , Elizabeta Nemeth  2 , Tomas Ganz  2 , Stephen T Oh  1
Affiliations

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Amy Zhou et al. Br J Haematol. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Amy Zhou has served as a consultant for Disc Medicine and receives research support from Rigel. Stephen T. Oh has served on scientific advisory board/consultant for Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, Incyte, Kartos Therapeutics, CTI BioPharma, Celgene/Bristol Myers Squibb, Gilead Sciences and Novartis. Tomas Ganz receives grant/research support from NIH, Akebia/Keryx and Sierra Oncology. He serves on the scientific advisory board/consultant/board of directors for ADARx, Alnylam, Akebia/Keryx, Ambys, American Regent, Disc Medicine, Global Blood Therapeutics, Gossamer Bio, Incyte, Intrinsic LifeSciences, Ionis, Pharmacosmos, Rockwell, Sierra Oncology and Silarus Pharma. He is a stock shareholder in Intrinsic LifeSciences and Silarus Pharma. Elizabeta Nemeth receives grant/research support from NIH. She serves on the scientific advisory board/consultant/board of directors for Disc Medicine, Intrinsic LifeSciences, Ionis Pharmaceuticals, Vifor Pharma, Protagonist Therapeutics, AstraZeneca/Fibrogen and Silarus Pharma. She is a stock shareholder in Intrinsic LifeSciences and Silarus Pharma. All other authors have no disclosures.

Figures

FIGURE 1
FIGURE 1
Hepcidin is elevated in patients with myelofibrosis and remains elevated with ruxolitinib treatment. (A) Hepcidin levels (ng/ml) in normal (N = 9) and MF patients (N = 99). p < 0.0001 by Mann–Whitney U test. (B) Hepcidin levels (ng/ml) in patients with primary MF (N = 49) and secondary MF (N = 50). p = 0.38 by Mann–Whitney U test. (C) Hepcidin levels (ng/ml) in normal (N = 9) and MF patients treated with (N = 21) and without ruxolitinib (N = 78). p < 0.0001 by Mann–Whitney U test
See this image and copyright information in PMC

References

    1. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–43. Epub 2012/02/07. doi:10.1016/j.bbamcr.2012.01.014.. - DOI - PMC - PubMed
    1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–10. Epub 2000/12/13. doi:10.1074/jbc.M008922200.. - DOI - PubMed
    1. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3. Epub 2004/10/30. doi:10.1126/science.1104742.. - DOI - PubMed
    1. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and iSn-depth discussion. Blood Cancer J. 2018;8(2):15. Epub 2018/02/11. doi:10.1038/s41408-018-0054-y.. - DOI - PMC - PubMed
    1. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, et al. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014;36(4):560–6. Epub 2014/03/19. doi:10.1016/j.clinthera.2014.02.016.. - DOI - PubMed

Publication types

LinkOut - more resources